Drug Shortage Report for TEVA-ALMOTRIPTAN
| Report ID | 19922 |
| Drug Identification Number | 02434849 |
| Brand name | TEVA-ALMOTRIPTAN |
| Common or Proper name | ALMOTRIPTAN |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | ALMOTRIPTAN |
| Strength(s) | 12.5MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 6 |
| ATC code | N02CC |
| ATC description | ANTIMIGRAINE PREPARATIONS |
| Reason for shortage | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | |
| Actual start date | 2017-08-17 |
| Estimated end date | 2019-08-30 |
| Actual end date | 2019-08-28 |
| Shortage status | Resolved |
| Updated date | 2019-08-29 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2017-08-21 | French | Compare |
| v1 | 2017-08-21 | English | Compare |